In a phase II trial among 108 cases of pretreated iCCA patients with FGFR2 fusion or rearrangement, infigratinib showed an overall response rate (ORR) of 23.1%, with a median duration of response of 5.0 months and a median progression-free survival (PFS) of 7.3 months [54]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.